News | January 06, 2026
Nia Therapeutics unveils first implantable brain interface for memory disorders
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
Our scientists found that toxicological data for most PFAS are incomplete or unavailable, leaving significant uncertainty about consumer safety
Elanco expects Befrena to launch in the US in the first half of 2026
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The study met its primary endpoint with flying colors
The primary goal of the collaboration is joint research into trending and next-generation molecules
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Subscribe To Our Newsletter & Stay Updated
